Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 70 children with migraine without aura, mean age 10; 61 completed
- Dose used in the study
- Ultramicronised PEA 600 mg a day
- Duration
- 3 months
- What was measured
- Monthly attack frequency, attack intensity on a 1 to 3 scale, monthly acute medication use
What the authors reported
Monthly attacks fell from 13.9 to 6.5 (p < 0.001) and 63.9 percent of children had at least a halving of attack frequency. Mean intensity fell from 1.67 to 1.16. Acute medication use halved. One child had mild nausea and light-headedness.
Limits of this study
Open label with no control group, which matters in migraine where placebo responses in children are large. Nine of 70 stopped early. The authors say the results cannot be considered reliable without a controlled trial. A study in children; nothing in it bears on unsupervised use. Authors declare no conflicts.
Source
PubMed 32377286 · doi:10.1155/2020/3938640
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.